Alesta Therapeutics

Established in 2021 and based in Leiden, Netherlands, Alesta Therapeutics operates as a biotechnology company that researches and develops small molecules for rare diseases. In August 2026, BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics from Droia Ventures, Thuja Capital, Frazier Lifesciences Acquisition Corporation, Novartis Venture Fund, RTW Investments, RV Invest, and SSI Strategy Holdings LLC for an upfront payment of USD 275 million and will receive additional payment of approximately USD 215 million upon achieving development and regulatory milestones. The firm as of January 2025, is led by its CEO, Ilan Ganot.

The company focuses on the development of innovative oral small molecules intended for the treatment of rare diseases. Their core products include ALE1, addressing hypophosphatasia (HPP), and ALE2, targeting Charcot-Marie-Tooth disease (CMT). ALE1 is designed to treat the full spectrum of HPP symptoms, which can affect bone and dental health, while ALE2 aims to mitigate chronic neurotoxicity associated with specific genetic alterations in CMT. These products are currently in the pre-clinical and clinical development stages, with ALE1 expected to enter clinical studies in 2025.

Alesta Therapeutics, as of January 2025, serves patients in the United States and Europe, specifically targeting a population of approximately 50,000 individuals with HPP in the US and 75,000 in Europe, alongside about 126,000 affected by CMT in the US and 2. 6 million worldwide. The August 2026 acquisition enables BioMarin Pharmaceutical Inc. to accelerate the development and commercialization of ALE1, an oral small-molecule therapy for hypophosphatasia.